Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Launched by LOMA LINDA UNIVERSITY · Jun 12, 2014

Keywords

ClinConnect Summary

Inclusion Criteria:

1. Diagnosis of idiopathic Parkinson's disease.
2. Age \> 40 years.
3. willingness and ability to comply with the study requirements and give informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.
• • 2. Presence of drug-induced dyskinesias
• • 3. Age\>40 years.
• • 4. Willingness and ability to comply with the study requirements and give informed consent.
• Exclusion Criteria:
• • 1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases.
• • 2. History of stereotaxic brain surgery.
• • 3. Clinical history of dementia.
• • 4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or substance dependence within previous 12 months.
• • 5. History of major hematological, renal, or hepatic abnormalities.
• • 6. Known coronary artery disease including angina or myocardial infarction within the last 6 months. Significant cardiovascular disease including cardiac failure, unstable angina or life-threatening arrhythmia within the last 6 months.
• • 7. History of stroke within the last 6 months.
• • 8. Abnormal EKG consistent with cardiac ischemia.
• • 9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral, sublingual, transdermal, inhalation, or aerosols).
• • 10. Malignant hypertension or SBP . 180 or \<90, or DBP .110 or \<50.
• • 11. History of priapism.
• • 12. Known history of retinitis pigmentosa.
• • 13. Positive pregnancy test.
• • 14. History of bleeding disorder.
• • 15. Patients with active peptic ulcer disease associated with bleeding.
• • 16. Unwillingness to use adequate contraceptive methods if of childbearing potential.
• • 17. Patients with medical or psychological condition or social circumstances that would impair their ability to participate in the study.
• • 18. Use of Viagra or any experimental drugs within 30 days of screening visit.